
    
The genomic variant c.4223G>A p.Trp1408Ter rs794726784 in the SCN1A gene is a nonsense mutation resulting in the introduction of a premature termination codon at amino acid position 1408 (Trp1408Ter). This variant has been identified in the context of severe myoclonic epilepsy of infancy (SMEI), also known as Dravet syndrome (DS), which is a rare and severe form of epilepsy that begins in infancy [4]. The c.4223G>A variant has been reported to be associated with a clinical phenotype characterized by severe mental decline and childhood epilepsies [3]. In a study involving mosaic parent information, this variant was found in a mother with undefined epilepsy, suggesting a potential link between the variant and the epilepsy phenotype [2].The SCN1A gene encodes the alpha-1 subunit of the voltage-gated sodium channel Na_v1.1, which is critical for the initiation and propagation of action potentials in neurons. Mutations in SCN1A can lead to a variety of epilepsy syndromes, with the c.4223G>A variant contributing to the loss of function of the sodium channel, thereby affecting neuronal excitability and leading to the clinical manifestations of SMEI [4].ClinVar has two pathogenic submissions for the rs794726784 variant, which is consistent with the reported clinical significance of this variant in the literature. The stop gained nature of this variant is expected to result in a truncated protein product that lacks critical functional domains necessary for the proper functioning of the sodium channel, contributing to the pathogenicity of the variant.

SCN1A遺伝子におけるゲノム変異c.4223G>A p.Trp1408Ter rs794726784はナンセンス変異であり、アミノ酸位置1408（Trp1408Ter）で早期終止コドンを導入する結果をもたらします。この変異は、乳児重症ミオクロニーてんかん（SMEI）としても知られるドラベ症候群（DS）の文脈で同定されています。ドラベ症候群は、乳児期に発症する稀で重症なてんかんの一形態です[4]。c.4223G>A変異は、重度の精神的退行および小児期てんかんを特徴とする臨床表現型と関連していると報告されています[3]。モザイク親に関する研究では、この変異が未定義のてんかんを持つ母親に見られ、この変異とてんかん表現型との潜在的な関連が示唆されました[2]。

SCN1A遺伝子は電位依存性ナトリウムチャネルNa_v1.1のα1サブユニットをコードしており、これはニューロンにおける活動電位の開始と伝播に重要です。SCN1Aの変異はさまざまなてんかん症候群を引き起こす可能性があり、c.4223G>A変異はナトリウムチャネルの機能喪失に寄与し、それによってニューロンの興奮性に影響を与え、SMEIの臨床症状を引き起こします[4]。

ClinVarにはrs794726784変異に関する2件の病原性提出があり、これは文献で報告されているこの変異の臨床的意義と一致しています。この変異の「ストップゲイン」性質は、ナトリウムチャネルの適切な機能に必要な重要な機能ドメインを欠いた切断タンパク質産物をもたらすと予想されており、変異の病原性に寄与しています。
    
## References
- [1] Viswanathan LG et al. (2023). "Phenotypic features of epilepsy due to sodium channelopathies - A single center experience from India." Journal of neurosciences in rural practice, 14(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38059254/)
- [2] Xu X et al. (2015). "Amplicon Resequencing Identified Parental Mosaicism for Approximately 10% of "de novo" SCN1A Mutations in Children with Dravet Syndrome." Human mutation, 36(9) [PubMed](https://pubmed.ncbi.nlm.nih.gov/26096185/)
- [3] Zeng B et al. (2023). "Identification of five novel SCN1A variants." Frontiers in behavioral neuroscience, 17() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38025388/)
- [4] Sun H et al. (2009). "[Mutation analysis of the SCN1A gene in severe myoclonic epilepsy of infancy]." Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 26(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/19350499/)
- [5] Л.Г. Кирилова et al. (2021). "Epileptic Encephalopathies in Children with Autistic Spectrum Disorders: from Molecular Genetic Diagnostics to Target Therapy" Психиатрия, психотерапия и клиническая психология,  [PubMed](https://doi.org/10.34883/pi.2021.12.2.006)
- [6] Genovese G et al. (2016). "Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia." Nature neuroscience, 19(11) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/27694994/)
- [7] Yang L et al. (2024). "Phase separation as a possible mechanism for dosage sensitivity." Genome biology, 25(1) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/38225666/)
- [8] Kusakabe M et al. (2019). "Synthetic modeling reveals HOXB genes are critical for the initiation and maintenance of human leukemia." Nature communications, 10(1) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/31266935/)
- [9] Woolston A et al. (2019). "Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer." Cancer cell, 36(1) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/31287991/)

    
## ClinVar Submissions
- **[RCV000180900](https://www.ncbi.nlm.nih.gov/clinvar/RCV000180900/)**: Severe myoclonic epilepsy in infancy
- **[RCV001527712](https://www.ncbi.nlm.nih.gov/clinvar/RCV001527712/)**: Generalized epilepsy with febrile seizures plus, type 2

    